Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 21, 2012 19:00 ET | Source: MediciNova, Inc.

MediciNova Completes Enrollment in Phase 2 MN-221 Trial Treating Patients Suffering from Acute Exacerbations of Asthma

SAN DIEGO, March 21, 2012 (GLOBE NEWSWIRE) -- MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange...
March 13, 2012 18:00 ET | Source: MediciNova, Inc.

MediciNova Receives Notice of a Japanese Patent Allowance for a Method of Treating Neuropathic Pain

SAN DIEGO, March 13, 2012 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange...
February 08, 2012 16:30 ET | Source: MediciNova, Inc.

MediciNova to Present at American Academy of Emergency Medicine Annual Meeting

SAN DIEGO, Feb. 8, 2012 (GLOBE NEWSWIRE) -- MediciNova Inc, a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (4875),...
February 01, 2012 06:00 ET | Source: MediciNova, Inc.

MediciNova Receives a Notice of Patent Allowance for a Method of Treating Progressive Multiple Sclerosis

SAN DIEGO, Calif., Feb. 1, 2012 (GLOBE NEWSWIRE) -- MediciNova Inc, a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange...
January 16, 2012 06:00 ET | Source: MediciNova, Inc.

MediciNova and University of Colorado Boulder Collaborate on Potential Novel Therapy for Traumatic Brain Injury

SAN DIEGO, Jan. 16, 2012 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka...
November 30, 2011 18:00 ET | Source: MediciNova, Inc.

MediciNova, Inc. Appoints Kousuke Nakata to Its Board of Directors

SAN DIEGO, Calif., Nov. 30, 2011 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities...
November 15, 2011 06:00 ET | Source: MediciNova, Inc.

MediciNova Reports Third Quarter 2011 Results

SAN DIEGO, Nov. 15, 2011 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka...
November 09, 2011 17:00 ET | Source: MediciNova, Inc.

MediciNova to Present at the Lazard Capital Markets Healthcare Conference

SAN DIEGO, Nov. 9, 2011 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka...
October 27, 2011 19:00 ET | Source: MediciNova, Inc.

MediciNova Announces Repeat Dose Clinical Trial With MN-221 in Chronic Obstructive Pulmonary Disease (COPD) Patients

SAN DIEGO, Oct. 27, 2011 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange...
October 13, 2011 19:00 ET | Source: MediciNova, Inc.

MediciNova to Receive $2.5 Million Payment From Kissei Pharmaceutical Co. Ltd. to Expand Clinical Development of the MN-221 Program

SAN DIEGO, Oct. 13, 2011 (GLOBE NEWSWIRE) -- MediciNova Inc., a biopharmaceutical company publicly traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities...